Over 264 million worldwide.

Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD) represents a significant mental health challenge, with emerging research into the efficacy of psychedelics like psilocybin and ketamine offering new avenues for treatment. Recent studies have demonstrated the potential of these compounds to alleviate symptoms, particularly in treatment-resistant cases of MDD.

What is Major Depressive Disorder (MDD)?

Major Depressive Disorder (MDD) is characterised by persistent feelings of sadness, loss of interest, and a variety of emotional and physical problems. It impacts daily functioning and is often accompanied by a range of symptoms, including fatigue, altered sleep patterns, appetite disturbances, and cognitive difficulties.

The underlying pathophysiology of MDD is complex and multifactorial, involving neurotransmitter imbalances (such as serotonin and norepinephrine), neuroinflammation, and dysregulation of the neuroendocrine system. Genetic, psychosocial, and environmental factors further contribute to its development.

MDD can lead to significant impairment in personal, social, and occupational domains, and it poses a serious risk factor for suicide. Current estimates indicate it affects a substantial global population, with many individuals remaining untreated or inadequately treated.

Current Treatments

Standard treatments for MDD typically include antidepressants (such as SSRIs and SNRIs), psychotherapy (including cognitive-behavioural therapy), and in some cases, electroconvulsive therapy (ECT) for severe cases. Treatment-resistant MDD often necessitates more complex approaches.

Psychedelic Effect Matrix

Systematic comparison of compound efficacy and evidence levels for Major Depressive Disorder (MDD).

Compound	Magnitude	Evidence	Consistency
Psilocybin Psilocybin demonstrates reliable efficacy in clinical studies for reducing depressive symptoms.	Large	High	Consistent
Ketamine Ketamine offers rapid relief from depressive symptoms, particularly in treatment-resistant cases.	Large	High	Consistent
MDMA While promising in PTSD, the effects on MDD are less consistently reported.	Medium	Moderate	Inconsistent
Ayahuasca Initial findings support anxiety and mood improvement; however, larger studies are needed.	Medium	Moderate	Inconsistent
Ibogaine Limited research exists; primarily investigated for substance use disorders.	Small	Low	Inconsistent

Psilocybin and Major Depressive Disorder (MDD)

Psilocybin, a naturally occurring psychedelic compound, has shown significant promise in alleviating depressive symptoms. Clinical trials indicate that psilocybin can lead to substantial reductions in depression and anxiety, often following a structured therapeutic protocol that combines the compound with psychotherapy. Its rapid onset and durable effects, particularly in treatment-resistant cases, have spurred interest in further exploration of its mechanisms and optimal clinical applications.

View full Psilocybin profile →

Ketamine and Major Depressive Disorder (MDD)

Ketamine, originally developed as an anaesthetic, has been repurposed to treat major depressive disorder due to its rapid antidepressant effects. Administered in sub-anesthesia doses, ketamine can produce marked improvements in depressive symptoms within hours, a stark contrast to the often delayed response seen with traditional antidepressants. Ongoing studies are investigating its long-term efficacy and the potential for developing ketamine-based protocols for chronic depression.

View full Ketamine profile →

Key Insights

1
Recent trials indicate that psilocybin can produce significant improvements in depressive symptoms with effects lasting up to six months.
2
Studies suggest that the response to psychedelics may vary significantly based on dosage and therapeutic context, highlighting the importance of tailored approaches.
3
Ketamine has emerged as a rapid-acting treatment option for MDD, showing effects within hours.
4
Research is increasingly focused on the mechanisms of action of psychedelics, revealing potential pathways connecting these compounds to neurogenesis and mood regulation.
5
Combining psychedelics with psychotherapy may enhance treatment outcomes and sustainability of benefits.

Industrial Landscape

Key players in this research space include organisations such as the Multidisciplinary Association for Psychedelic Studies (MAPS), the Beckley Foundation, and various academic institutions conducting clinical trials in psychedelic therapy.

Quick Indicators

PrevalenceOver 264 million worldwide.

Research Footprint

0Trials

0Papers

\"Ongoing clinical evaluations are investigating Major Depressive Disorder (MDD) as a primary indication for various psychedelic compounds.\"

Key Organizations

4 Connected

Delix Therapeutics

Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.

MAPS

The description of the stakeholder

Lykos Therapeutics

Longer description of Lykos .. lorem ipsum ..

Leiden University

Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.